Letters by company
Royalty Pharma plc
4 letters discussing RPRX. Everything written about it on this site is on its ticker page.
- Patient Capital Management 1Q26 Portfolio Activity & Attribution Patient Opportunity Equity Strategy added Adobe after the software selloff and replaced FBTC with IBIT to retain Bitcoin exposure, while selling Alibaba at estimated intrinsic value and exiting Mattel and Peloton to fund new ideas. The strategy argues that concentrated energy exposure offers an anti-fragile diversifier, with offshore drilling and pipeline constraints supporting Noble, Seadrill and Energy Transfer. 1Q26 -6.0% ADBE $110BCHYM $12BET $73BIBIT $173B
- Patient Capital Management 2Q26 Portfolio Activity & Attribution Opportunity Equity added Adyen, Global Payments, Genius Sports, Fidelity Wise Origin Bitcoin Fund and QXO preferreds while exiting iShares Bitcoin Trust, Dave & Buster's and Noble. The strategy argues that depressed expectations in managed care, biotech, payments, offshore drilling and Adobe obscure durable earnings power and consolidation opportunities. 2Q26 +17.3% ADBE $110BADYEN $39BCVS $120BFBTC
- Patient Capital Management 4Q25 Portfolio Activity and Attribution Patient Opportunity Equity Strategy added long-dated Biogen calls, Chime and Fiserv while exiting Angi, citing Biogen’s Alzheimer’s pipeline, Chime’s underserved-consumer banking platform and Fiserv’s reset under new leadership. The strategy argues that health-care holdings remain undervalued and that idiosyncratic stock selection, rather than AI exposure, drives its edge. fourth quarter of 2025 +6.0% BIIB $33BCHYM $12BCOIN $45BFBTC
- Patient Capital Management 3Q25 Portfolio Recap Patient Opportunity Equity Strategy converted and trimmed Precigen after Papzimeos won early FDA approval, while retaining conviction in its commercial opportunity and pipeline. The strategy added aggressively to UnitedHealth during its sell-off and increased selected laggards including Crocs, Mattel, IAC and Biogen while keeping exposure to momentum areas. 3Q25 +14.1% PGEN $2.6BUNH $350BBIIB $33BCROX $5.9B
